Ratings Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.793 ^USD	+4.26%		-2.79%	-58.04%

Apr. 17	Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	MT
Apr. 17	Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
BIONANO GENOMICS, INC.	-58.04%	46.57M	D+
THERMO FISHER SCIENTIFIC	+8.35%	209B	B
DANAHER CORPORATION	+9.41%	175B	B-
INTUITIVE SURGICAL, INC.	+11.75%	131B	B-
BOSTON SCIENTIFIC CORPORATION	+19.34%	99.98B	A-
SIEMENS HEALTHINEERS AG	-0.84%	61.12B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.08%	52.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-2.10%	46.5B	B+
AGILENT TECHNOLOGIES, INC.	+0.10%	39.24B	A
GE HEALTHCARE TECHNOLOGIES INC.	+11.50%	38.47B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes